ID   SLR26
AC   CVCL_V612
SY   SLR 26
DR   BioGRID_ORCS_Cell_line; 705
DR   BioSample; SAMN10988407
DR   cancercelllines; CVCL_V612
DR   Cell_Model_Passport; SIDM01338
DR   Cosmic; 2520644
DR   DepMap; ACH-000600
DR   GEO; GSM374473
DR   GEO; GSM482712
DR   PharmacoDB; SLR26_1426_2019
DR   Progenetix; CVCL_V612
DR   Wikidata; Q54954877
RX   PubMed=12907621;
RX   PubMed=19470766;
RX   PubMed=22949125;
RX   PubMed=25984343;
RX   PubMed=28489074;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   Doubling time: 55 hours (PubMed=25984343).
CC   Omics: Deep exome analysis.
CC   Omics: shRNA library screening.
CC   Genome ancestry: African=1.17%; Native American=0%; East Asian, North=1.33%; East Asian, South=1.5%; South Asian=0%; European, North=65.36%; European, South=30.63% (PubMed=30894373).
CC   Miscellaneous: STR profile from personal communication of von Teichman A.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 11
ST   D16S539: 11
ST   D18S51: 13
ST   D21S11: 28,31
ST   D3S1358: 14
ST   D5S818: 10,12
ST   D7S820: 10
ST   D8S1179: 13
ST   FGA: 19
ST   Penta D: 15
ST   Penta E: 10,13
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 14,18
DI   NCIt; C4033; Clear cell renal cell carcinoma
DI   ORDO; Orphanet_319276; Clear cell renal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 30-01-24; Version: 16
//
RX   PubMed=12907621;
RA   Tatsumi T., Herrem C.J., Olson W.C., Finke J.H., Bukowski R.M.,
RA   Kinch M.S., Ranieri E., Storkus W.J.;
RT   "Disease stage variation in CD4+ and CD8+ T-cell reactivity to the
RT   receptor tyrosine kinase EphA2 in patients with renal cell
RT   carcinoma.";
RL   Cancer Res. 63:4481-4489(2003).
//
RX   PubMed=19470766; DOI=10.1158/0008-5472.CAN-09-0146;
RA   Beroukhim R., Brunet J.-P., Di Napoli A., Mertz K.D., Seeley A.,
RA   Pires M.M., Linhart D., Worrell R.A., Moch H., Rubin M.A.,
RA   Sellers W.R., Meyerson M.L., Linehan W.M., Kaelin W.G. Jr.,
RA   Signoretti S.;
RT   "Patterns of gene expression and copy-number alterations in von-Hippel
RT   Lindau disease-associated and sporadic clear cell carcinoma of the
RT   kidney.";
RL   Cancer Res. 69:4674-4681(2009).
//
RX   PubMed=22949125; DOI=10.1002/ijc.27822;
RA   Pawlowski R., Muhl S.M., Sulser T., Krek W., Moch H., Schraml P.;
RT   "Loss of PBRM1 expression is associated with renal cell carcinoma
RT   progression.";
RL   Int. J. Cancer 132:E11-E17(2013).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=28489074; DOI=10.1038/ncomms15165;
RA   Sinha R., Winer A.G., Chevinsky M., Jakubowski C., Chen Y.-B., Dong Y.-Y.,
RA   Tickoo S.K., Reuter V.E., Russo P., Coleman J.A., Sander C.,
RA   Hsieh J.J.-D., Hakimi A.A.;
RT   "Analysis of renal cancer cell lines from two major resources enables
RT   genomics-guided cell line selection.";
RL   Nat. Commun. 8:15165.1-15165.10(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//